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Abstract
Background: Genetically determined differences in N-acetylation capacity have proved to be
important determinants of both the effectiveness of therapeutic response and the development of
adverse drug reactions and toxicity during drug treatment. NAT2PRED is a web-server that allows
a fast determination of NAT2 acetylation phenotype from genotype data without taking the extra
step of reconstructing haplotypes for each individual (publicly available at http://
nat2pred.rit.albany.edu). However, the classification accuracy of NAT2PRED needs to be assessed
before its application can be advocated at a large scale.
Methods: The ability of NAT2PRED to classify individuals according to their acetylation status
(slow, intermediate and rapid acetylators) was evaluated in a worldwide dataset composed of 56
population samples (8,489 individuals) from four continental regions.
Results: NAT2PRED correctly identified slow acetylators with a sensitivity above 99% for all
populations outside sub-Saharan Africa. Nevertheless, NAT2PRED showed a poor ability to
distinguish between intermediate and rapid acetylators, with a classification error rate reaching up
to 10% in the non-African samples.
Conclusion: NAT2PRED is an excellent tool to infer the individual acetylation status from NAT2
genotype data when the main interest is to distinguish slow acetylators from the others. This should
facilitate the determination of the individual acetylation status in routine clinical practice and lead
to better monitoring of risks associated with cancer and adverse drug reactions.
Background
The human acetylation polymorphism is one of the most
intensively studied pharmacogenetic traits that underlie
interindividual and interethnic differences in response to
xenobiotics. Genetically determined differences in N-
acetylation capacity have proved to be important determi-
nants of both the effectiveness of therapeutic response
and the development of adverse drug reactions and toxic-
ity during drug treatment [1,2]. Some of the drugs
excreted by acetylation are crucial in the treatment of dis-
eases representing a worldwide concern, such as tubercu-
losis, AIDS-related complex diseases, and hypertension.
Moreover, numerous association studies have linked the
acetylation phenotype to susceptibility to a variety of
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being those regarding urinary bladder cancer, asthma and
other allergic disorders [3-6].
Single nucleotide polymorphisms (SNPs) in the coding
region of the NAT2 gene determine the acetylation pheno-
type. Thanks to the well-established genotype-phenotype
correlation at this locus, the individual acetylation status
can be reliably predicted from the haplotype combination
at NAT2, according to the acknowledged classification of
NAT2 haplotypes into either low-activity or fully func-
tional alleles (see the consensus NAT2 gene nomenclature
website: http://www.louisville.edu/medschool/pharma
cology/NAT.html). Slow, intermediate and rapid acetyla-
tors are defined as carriers of zero, one or two functional
haplotypes, respectively. Many studies did not distinguish
between rapid and intermediate acetylators, categorizing
both types of subjects as rapid acetylators.
Determining the linkage phase of SNP alleles along the
coding sequence of NAT2 is crucial to unequivocally
assign an individual's multi-site NAT2 genotype to a par-
ticular combination of two multilocus haplotypes and to
correctly infer his acetylation status. Ambiguous NAT2
genotyping data that may lead to patient misclassification
appear indeed to be common in human populations [7].
Special analytical techniques have been designed to
unambiguously determine the allocation of SNP alleles to
either DNA strand. However, molecular haplotyping
methods are labour-intensive and expensive and are not
suitable for routine clinical applications. A cheap and
straightforward alternative for haplotype reconstruction is
the use of computational algorithms. Several studies have
demonstrated the high effectiveness of haplotype recon-
struction algorithms in the particular case of the NAT2
gene by comparing the computationally inferred haplo-
types to the real ones resolved through the use of molecu-
lar haplotyping techniques [7-9]. But such in silico
approaches may not be convenient to clinicians not famil-
iar with computational haplotype analysis. Moreover,
algorithmic techniques are statistical and require the anal-
ysis of a population rather than a single or a few individ-
uals.
To circumvent these limitations, Kuznetsov et al. [10]
have developed a web-server NAT2PRED that allows a fast
determination of NAT2 acetylation phenotypes (slow,
intermediate, and rapid) from the unphased genotype
data at six polymorphic positions in NAT2. These six SNPs
are the most commonly reported ones in surveys of NAT2
sequence variation in human populations [11].
NAT2PRED alleviates the need of reconstructing haplo-
types by implementing a supervised pattern recognition
method that was trained on the NAT2 genotyping data of
1,377 subjects of known acetylation status. This tool is
publicly available http://nat2pred.rit.albany.edu and has
a simple intuitive user interface. It showed a nearly perfect
classification accuracy of 99.9% in a sample mostly com-
posed of Caucasians [10]. However, it remains unclear to
what extent this tool can be applied to individuals from
any ethnicity since it was developed on a dataset where
94% of subjects were Caucasian. The accuracy of
NAT2PRED needs to be assessed before its application can
be advocated at a large scale.
The objective of the present study was to empirically eval-
uate the performance of NAT2PRED in a wide collection
of population samples worldwide. To this end, we per-
formed an extensive survey of the literature to identify
those samples that were adequately genotyped for all the
common SNPs in NAT2. In total the collected data con-
sisted of 8,489 individuals from 56 human populations
representing major geographic regions: sub-Saharan
Africa (12 samples), Europe and North Africa (23), Cen-
tral/South Asia (5), East Asia (13), and America (3). In
each sample, NAT2 haplotypes were reconstructed using
either molecular or computational methods. Therefore,
these data provided an opportunity to compare, for each
subject, the acetylation status inferred by NAT2PRED
from the unphased NAT2 genotype data with the "true"
one predicted from the pair of haplotypes reconstructed
through molecular or computational haplotyping.
NAT2PRED correctly identified slow acetylators with a
sensitivity above 99% for all populations outside sub-
Saharan Africa.
Methods
We selected from published reports up to November 2009
all the population samples that were genotyped for the
seven most common SNPs in NAT2 (191G>A
(rs1801279), 282C>T (rs1041983, rs59855457), 341T>C
(rs1801280, rs56935242), 481C>T (rs1799929,
rs60310310), 590G>A (rs1799930, rs60190029),
803A>G (rs1208, rs56599719, rs58999469), and 857G>A
(rs1799931, rs58803786)) and for which genotype fre-
quency data were available in the paper. We also included
those non-African samples that were genotyped for all
SNPs except SNP 191G>A as this is rare in non-African
populations. The final dataset used for the present study
describe 56 population samples from throughout the
world, representing 8,489 individuals. A summary
description of the data set is provided in Additional File 1.
In each sample, NAT2 haplotypes were either directly
resolved using molecular-haplotyping techniques
(through allele-specific PCR and restriction mapping) or
were computationally inferred from the unphased multi-
locus genotypes using statistical algorithms (based either
on a parsimony, maximum-likelihood, or Bayesian
approach). For some samples, a combination of the twoPage 2 of 6
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individual was then predicted by assuming that the
homozygous or compound heterozygous genotype for
two haplotypes of the series NAT2*4, NAT2*11, NAT2*12
or NAT2*13 results in the rapid acetylator status, the
occurrence of one of these haplotypes in combination
with a haplotype of the series NAT2*5, NAT2*6, NAT2*7
or NAT2*14 results in the intermediate acetylator status
and the occurrence of two haplotypes of the series
NAT2*5, NAT2*6, NAT2*7 or NAT2*14 results in the
slow acetylator phenotype.
Besides, NAT2PRED was applied to the unphased geno-
type data of each sample (at the six polymorphic positions
282, 341, 481, 590, 803, and 857) to provide an inferred
acetylation status that was compared to the "true" one
predicted from the diplotype configuration at NAT2. The
web-server was used in the standard way, by specifying the
genotype at each polymorphic position using radio but-
tons and clicking the 'Submit' button. We retained for
each subject the final prediction (i.e., the phenotype with
the highest probability). The performance of NAT2PRED
was measured by computing in each sample the classifica-
tion error rate, which is the proportion of individuals
whose acetylation status was incorrectly inferred by the
web-server. The classification error rate of NAT2PRED was
evaluated by considering either two (slow vs. others) or
three (slow vs. intermediate vs. rapid) phenotypic classes
for the acetylation status.
Results and discussion
The classification error rates of NAT2PRED in each sample
for both classification issues (two or three acetylation phe-
notypes) are shown in Figure 1 (see Additional File 1 for
the exact numbers). The performance of this tool in each
of the five world regions investigated is summarized in
Table 1. NAT2PRED performed poorly in almost all sub-
Saharan African samples investigated, except in the two
Ethiopian samples where it correctly classified 100% of
subjects into rapid, intermediate and slow acetylators.
Such a poor performance is not surprising in view of the
omission by the supervised learning classifier imple-
mented in NAT2PRED of the functional SNP 191G>A
which, although monomorphic in most worldwide popu-
lations, occurs at an appreciable frequency in many sub-
Saharan African populations (up to 23%) and accounts
for a sizeable portion of the slow acetylators encountered
in these populations [11,12]. By contrast, NAT2PRED
achieved a high classification accuracy in all the other
world regions. In particular, individuals with a slow
acetylation phenotype were correctly identified as slow
acetylators with a sensitivity above 99% for all popula-
tions outside sub-Saharan Africa. Conversely, NAT2PRED
showed a poor ability to distinguish between intermedi-
ate and rapid acetylators, with a classification error rate
reaching up to 10% in the non-African samples.
It is important to note that for most of the samples inves-
tigated, NAT2 haplotypes were not actually determined by
a molecular resolution of mutation linkage patterns but
were rather inferred through computational methods (see
Additional File 1). As real NAT2 haplotypes may be quite
different from those calculated by computational infer-
ence [7], it is of high relevance to evaluate the perform-
ance of NAT2PRED in only those samples where the real
NAT2 haplotypes were determined. There are only six
population samples where molecular techniques were
used to reconstruct haplotypes and applied to the whole
set of individuals. In the single African sample (Tswana
from South Africa), NAT2PRED showed a poor classifica-
tion accuracy with a classification error rate of 10% and
16% when considering two (slow vs. others) or three
Table 1: Classification error rates of NAT2PRED in each geographic regiona.
Classification error rate (%)
Two acetylation phenotypes b Three acetylation phenotypes c
Sub-Saharan Africa (n = 617) 6.81% [0-14%] 14.26% [0-30%]
Europe and North Africa (n = 4,391) 0.32% [0-1%] 0.98% [0-8%]
Central/South Asia (n = 757) 0.53% [0-1%] 3.57% [0-10%]
East Asia (n = 2,346) 0.09% [0-0.2%] 1.71% [0-8%]
America (n = 378) 0% 2.12% [0-3%]
Values are the classification error rates of NAT2PRED when all population samples within a geographic area were pooled into a single sample. The 
range of variation of the classification error rate across individual samples is indicated in square brackets.
aSee Figure 1 for the population composition of each geographic area.
bClassification error rate when two phenotypic classes are considered: slow vs. other acetylators (intermediate and rapid acetylators pooled 
together).
cClassification error rate when three phenotypic classes are considered: slow, intermediate and rapid acetylators.Page 3 of 6
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Classification error rates of NAT2PRED in the 56 worldwide samplesFigure 1
Classification error rates of NAT2PRED in the 56 worldwide samples. The classification accuracy of NAT2PRED was 
evaluated using either three phenotypic classes (slow, intermediate and rapid acetylators; hatched area) or two phenotypic 
classes (slow and other acetylators; black area) for the acetylation status. Single populations are reported on the left side of the 
plot, with sample sizes (number of individuals) in brackets. Geographic areas are indicated on the right side, as follows: SSAF-
RICA, sub-Saharan Africa; EUROPE/NORTH AFRICA, Europe and North Africa; CSASIA, Central and South Asia; EAST ASIA, 
East Asia; AME, America. The assignment of populations to one of the five world regions was based on the origin of the popu-
lation, in effect ignoring the past 1,000 years of known human migration (e.g., people of European descent in the United States 
were assigned to Europe).
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acetylation status, respectively. In the five remaining non-
African samples, the ability of NAT2PRED to distinguish
slow acetylators from the others was very high with an
average classification error rate of only 0.5%, ranging
from 0% in UK Caucasians and Nicaraguans to 1.2% in
Dravidian Indians. This means that in 99.5% of cases,
NAT2PRED correctly identified slow acetylators in the
same way the usual procedure did (that is, by reconstruct-
ing the real haplotypes through molecular techniques and
by inferring the individual acetylation status from the
haplotype combination at NAT2). On the other hand, a
poorer performance was observed when intermediate
acetylators were to be distinguished from rapid acetylators
in these five samples (average error rate of 2.6%, ranging
from 0% to 10.2%).
Conclusion
Our results show that NAT2PRED is an excellent tool to
infer the individual acetylation status from NAT2 geno-
type data when the main interest is to distinguish slow
acetylators from the others. Its classification error rate is
indeed too high to ensure a reliable discrimination
between intermediate and rapid acetylators. However,
since the slow acetylator phenotype is the one which
exhibits today the strongest association with susceptibility
to bladder cancer and adverse drug reactions [2,3], the
web-server NAT2PRED should be of great use in clinical
laboratories. This should facilitate the determination of
the individual acetylation status in routine clinical prac-
tice and lead to better monitoring of risks associated with
cancer and adverse drug reactions. On the other hand,
NAT2PRED must be used with caution for patients whose
population of origin contains a sizeable frequency of SNP
191G>A. This concerns populations of African origin but
also several non-African populations, notably South-
European and South-American populations, where this
SNP has been identified, probably as a consequence of
genetic admixture with Africans [13]. In particular, a fre-
quency above 1% has been reported for the 191A allele in
Spanish (1.4%) [7], in Coyaima from Colombia (3.5%)
[14], in Brazilians from Rio de Janeiro (4.7%) [15], and in
Brazilians from Goiàs (2.4%) [15].
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